Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials
HELSINKI, 3rd February 2025. Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, announced today it has closed a EUR 7 million financing. The funding round was led by new investors Fåhraeus Startup and Growth AB (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund. FSG and EIC Fund were joined by leading Finnish investors, including Jenny and Antti Wihuri Foundation, Innovestor and Gösta Serlachius Fine Arts Foundation.
